Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Eben Rosenthal
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07493447CT.gov Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Meningioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Panitumumab-Irdye800 (this asset) | Eben Rosenthal | Early P1 | C · 39 |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Fludarabine | Essen Biotech | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Anti-Ny Eso-1 Mtcr Pbl | National Cancer Institute (NCI) | P2 | B |
| Rvp-001 | Reveal Pharmaceuticals Inc. | P2 | B |
| (S)-(-)-Perillyl Alcohol | Neonc Technologies, Inc. | P2 | CCC |
| Therapeutic Allogeneic Lymphocytes | City of Hope Medical Center | P1 | CC |
| Olaparib | Fundación de investigación HM | P1/2 | CC |
+11 more in the Meningioma cohort
Other indications for Panitumumab-Irdye800
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P1/2 | CC · 43 |
| Acoustic Neuroma | — | Early P1 | C · 39 |
| Brain Cancer | — | Early P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Panitumumab-Irdye800 in Meningioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/panitumumab-irdye800-meningioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →